October 6, 2009 – Boston Scientific Corp. released data during TCT 2009 from the TAXUS ATLAS clinical program, a series of global, prospective, single-arm trials evaluating the TAXUS Liberté Paclitaxel-Eluting Stent System in a variety of lesions and patient groups.

October 5, 2009 – The National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) has awarded a grant to the American College of Cardiology (ACC) in partnership with the Society of Thoracic Surgeons (STS) to study the comparative effectiveness of the two forms of coronary revascularization – percutaneous coronary intervention (PCI) and coronary artery bypass graft (CAB

October 5, 2009 – Boston Scientific released its CE-marked, next-generation iLab System Software for the iLab Intravascular Ultrasound (IVUS) Imaging System during TCT 2009, which includes iMap tissue characterization, similar to Volcano’s Virtual Histology IVUS. The company said it is awaiting FDA clearance for the software.

October 5, 2009 – A new analysis reaffirms that Lexiscan (regadenoson) Injection, the first selective A2A adenosine receptor agonist approved for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress, requires infrequent use of the drug aminophylline to reverse its effect in the case of adverse events.

October 2, 2009 – Cardiovascular magnetic resonance (CMR) in the evaluation of patients with heart failure (HF) “will expand substantially in the coming years,” according to the authors of a study published in October 2009 issue of the Journal of American College of Cardiology.

October 2, 2009 – Resverlogix Corp. said this week results from the company's second clinical trial for the drug RVX-208 showed it increases the production of plasma ApoA-I, the key cardioprotective protein in high-density lipoprotein (HDL).